Combined L-carnosine and Cognitive Training on Cognition in Schizophrenia
Schizophrenia
Enrolment: 60 · Results not recorded
Nutraceutical · ChEMBL entry CHEMBL242948 is the L-enantiomer (beta-alanyl-L-histidine, chirality=1); the D-enantiomer studied here has no separate ChEMBL record, so this is a same-molecule different-stereochemistry match and is flagged for manual review. No ChEMBL mechanism_of_action record; carnosine acts as an endogenous dipeptide antioxidant and carbonyl scavenger.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Schizophrenia
Enrolment: 60 · Results not recorded
Peripheral Arterial Disease
Enrolment: 104 · Results not recorded
Peripheral Neuropathy · Cancer
Enrolment: 65 · Results not recorded
Type 1 Diabetes · Diabetic Nephropathy
Enrolment: 90 · Results not recorded
Gastroesophageal Reflux
Enrolment: 60 · Results not recorded
Multiple Sclerosis
Enrolment: 45 · Results not recorded
Inflammation · Sarcopenia
Enrolment: 60 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Spinal cord compression (aneurysm clip, 24 g) at T6-T7
D-carnosine but not L-carnosine reduced inflammation and tissue injury and improved motor recovery after spinal cord injury.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
Model: Acute traumatic spinal cord injury produced after laminectomy with a 70 g closing force aneurysm clip (Yasargil FE 721)
Carnosine, methylprednisolone and their combination significantly raised plasma irisin and irisin immunoreactivity in brain and spinal cord of injured rats compared with control and sham; no functional or histological recovery endpoint was reported, so clinical benefit remains unclear.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.